Kymera Therapeutics KYMR 深 沪
等待开盘 11-06 09:30:00 美东时间
59.89
-0.020
-0.03%
华盛通- 最 高60.81
- 今 开59.07
- 成交量 77.18万股
- 最 低 57.4301
- 昨 收 59.91
- 总市值 42.82亿
- 52周最高 63.9599
- 市盈率 静 --
- 换手率 1.08%
- 52周最低 19.445
- 委 比 -83.49%
- 总股本 7149.76万
- 历史最高 91.92
- 量 比 1.14
- 振 幅 5.64%
- 历史最低 9.60
- 每 手 1
- 风险率 9.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多B. Riley Securities Remains a Buy on Kymera Therapeutics (KYMR)
In a report released yesterday, Mayank Mamtani from B. Riley Securities maintai...
今天 13:55
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
今天 09:55
10 Analysts Have This To Say About Kymera Therapeutics
Across the recent three months, 10 analysts have shared their insights on Kymer...
11-05 19:45
Kymera Therapeutics Q3 EPS $(0.94) Misses $(0.83) Estimate, Sales $2.764M Miss $18.852M Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.83) by 13.12 percent. This is a 14.63 percent decrease over losses of $(0.82) per share
11-04 20:02
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Guggenheim Assumes Kymera Therapeutics at Buy, Announces Price Target of $90
Guggenheim analyst Brad Canino assumes Kymera Therapeutics (NASDAQ:KYMR) with a Buy rating and announces Price Target of $90.
11-03 21:14
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Kymera Therapeutics announced its participation in multiple investor events in November 2025, including fireside chats at conferences in Boston, Palm Beach, New York, and London. The events aim to discuss the company’s targeted protein degradation (TPD) technology for immunological diseases. Live webcasts and replays of the presentations will be available on Kymera’s website.
11-03 12:00
Kymera Therapeutics Presents New Preclinical Data For KT-579, Oral IRF5 Degrader, Demonstrating Disease-Modifying Activity Across Multiple Immuno-Inflammatory Diseases, At ACR 2025
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically
10-27 19:12
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
Kymera Therapeutics announced new preclinical data for KT-579, a potent, selective, oral IRF5 degrader, showing disease-modifying activity across lupus and rheumatoid arthritis models. KT-579 targets IRF5, a master regulator of immune responses, suppressing pro-inflammatory pathways. Phase 1 testing is expected to begin in early 2026. The data, presented at the ACR Convergence Annual Meeting, highlight KT-579's ability to reduce autoimmune sympto...
10-27 11:00
